The marketing around Ozempic, Wegovy, Mounjaro, and Zepbound is relentless — and is only telling you one very small part of the story.Louise Adams is a clinical psychologist, author, podcaster and founder of Untrapped. She has spent more than 20 years in the non-diet and Health at Every Size field. She recently co-authored a peer-reviewed paper — GLP-1 Medication for Weight Loss: A Triumph of Marketing Over Patient Care — which cut through the noise to look at what the clinical trials actually show, what the drug companies are not highlighting, and why informed consent is so critical before taking a weight loss medication.This episode is not about telling you whether to take a GLP-1 medication or not. It is about making sure that whatever you decide, you have the full picture.In this episode we coverWhy almost everyone talking about GLP-1s in a positive light has a financial relationship with at least one drug company — and what that means for the information you are receivingWhat the clinical trials actually show about weight loss outcomes — including the significant variation in results, the plateau at around 12 months, and what happens when you stopWhy GLP-1 medications are weight suppression drugs, not a cure — and why your body's response to that is not a personal failureThe side effects that are not getting the spotlight they deserve, including gastric paralysis, pancreatitis, and the growing number of lawsuits citing lack of informed consentHow the framing of larger body size as a disease was built — and why the comparison to how other conditions have been pathologised throughout history mattersThe difference between weight-dependent and weight-independent health outcomes — including why cardiovascular benefits from GLP-1s appear to occur regardless of whether you lose weightHow to ask better questions of your health provider, and which weight-inclusive resources can help you do thatA practical framework for making a genuinely informed decision: what do you actually want from this, what are the short and long-term pros and cons, and which of your goals are truly weight-dependentResources mentioned in this episodeLouise Adams' paper: GLP-1 medication for weight loss, a triumph of marketing over patient care -- https://www.tandfonline.com/doi/full/10.1080/21604851.2026.2646492Louise Adams -- meet Louise and her work: https://untrapped.com.au/meet-louise/Louise Adams untrapped academy, newsletter and podcast All Fired Up: https://untrapped.com.auRagen Chastain's Weight and Healthcare Substack: https://weightandhealthcare.substack.com/AWIM GLP-1 Informed Consent document: https://sizeinclusivemedicine.org/wp-content/uploads/2024/03/MSSI-GLP1-Informed-Consent-10.pdfHAES Health Sheets: https://haeshealthsheets.com/Association for Size Inclusive Medicine: https://weightinclusivemedicine.orgIf this episode resonated with youShare it with a woman in your life who is being targeted by the GLP-1 marketing machine — and who deserves the full story before she decides.Learn more about feminist health coaching and a completely different approach to your health and your body. The Wait.What? newsletter is a good place to start.https://emmawright.co.nz/waitwhat/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.